Nasopharyngeal Carcinoma Clinical Trials

149 recruitingLast updated: June 17, 2026

There are 149 actively recruiting nasopharyngeal carcinoma clinical trials across 13 countries. Studies span Phase 2, Phase 3, Not Applicable, Phase 1, Early Phase 1. Top locations include Guangzhou, Guangdong, China, Nanning, Guangxi, China, Nanchang, Jiangxi, China. Updated daily from ClinicalTrials.gov.


Nasopharyngeal Carcinoma Trials at a Glance

149 actively recruiting trials for nasopharyngeal carcinoma are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 53 trials, with the heaviest enrollment activity in Guangzhou, Nanning, and Nanchang. Lead sponsors running nasopharyngeal carcinoma studies include Sun Yat-sen University, Ming-Yuan Chen, and Jiangxi Provincial Cancer Hospital.

Browse nasopharyngeal carcinoma trials by phase

Treatments under study

About Nasopharyngeal Carcinoma Clinical Trials

Looking for clinical trials for Nasopharyngeal Carcinoma? There are currently 91 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Nasopharyngeal Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Nasopharyngeal Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 149 trials

Recruiting
Phase 1

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Nasopharyngeal CarcinomaKidney CancersEsthesioneuroblastoma+7 more
National Cancer Institute (NCI)120 enrolled1 locationNCT06479811
Recruiting
Phase 2

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

Stage IV Nasopharyngeal Carcinoma AJCC v8Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Carcinoma
National Cancer Institute (NCI)50 enrolled92 locationsNCT05904080
Recruiting
Phase 2

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

Stage IV Nasopharyngeal Carcinoma AJCC v8Stage III Nasopharyngeal Carcinoma AJCC v8Stage II Nasopharyngeal Carcinoma AJCC v8
National Cancer Institute (NCI)50 enrolled85 locationsNCT06064097
Recruiting
Phase 2

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Stage IV Nasopharyngeal Carcinoma AJCC v8Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharyngeal Carcinoma
National Cancer Institute (NCI)156 enrolled88 locationsNCT06029270
Recruiting
Phase 3

RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma (NPC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences651 enrolled1 locationNCT07590024
Recruiting

Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC

Nasopharyngeal Carcinoma (NPC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences900 enrolled1 locationNCT07618078
Recruiting
Phase 2

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaStage III Laryngeal Cancer AJCC v8+19 more
National Cancer Institute (NCI)44 enrolled6 locationsNCT06980038
Recruiting
Phase 3

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal CarcinomaHigh-Risk CancerMaintenance Therapy
Jiangxi Provincial Cancer Hospital264 enrolled3 locationsNCT06277050
Recruiting
Phase 2

CD70-targeted immunoPET Imaging of Malignant Cancers

LymphomaRenal CancerMantle Cell Lymphoma+4 more
RenJi Hospital300 enrolled1 locationNCT06852638
Recruiting
Phase 1

Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

NeuroblastomaNasopharyngeal CarcinomaRhabdomyosarcoma+7 more
Sun Yat-sen University51 enrolled1 locationNCT07584499
Recruiting
Phase 3

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

ChemotherapyRadiotherapyImmune Checkpoint Inhibitor+1 more
Sun Yat-sen University380 enrolled3 locationsNCT05941741
Recruiting
Phase 3

Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition

Nasopharyngeal CarcinomaNutrition Therapy
Sun Yat-sen University266 enrolled1 locationNCT04436965
Recruiting
Phase 3

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Nasopharyngeal Carcinoma
Sun Yat-sen University212 enrolled12 locationsNCT05340491
Recruiting
Phase 3

PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University212 enrolled12 locationsNCT03907826
Recruiting
Phase 2

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen33 enrolled1 locationNCT07581821
Recruiting

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

Nasopharyngeal CarcinomaMulti-omics TechniqueRecurrent and Metastatic Nasopharyngeal Carcinoma+1 more
Sun Yat-sen University50 enrolled1 locationNCT06197776
Recruiting
Phase 2

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Sun Yat-sen University148 enrolled1 locationNCT06323239
Recruiting
Phase 1Phase 2

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Nasopharyngeal Cancinoma (NPC)Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharynx Carcinoma
Sun Yat-sen University148 enrolled1 locationNCT06802835
Recruiting
Not Applicable

Plasma Radiofrequency Ablation at Low Temperature Versus Electrocautery Block Resection at High Frequency for Localized Recurrent Nasopharyngeal Carcinoma

SurgeryRecurrent Nasopharyngeal Carcinoma
Sun Yat-sen University500 enrolled3 locationsNCT04425265
Recruiting
Phase 2

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Non-small Cell Lung CancerSolid TumorNasopharyngeal Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.570 enrolled1 locationNCT06475300